Ivonescimab Monotherapy Outperforms Pembrolizumab in WEB HARMONi-2 Trial

Groundbreaking Results to be Presented at SMMT Summit on September 8, 2024

SMMT Summit Breaking News: Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy in Head-to-Head Trial

The SMMT Summit will feature a groundbreaking presentation on the results of the WEB HARMONi-2 trial, which evaluated the efficacy of ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic bladder cancer.

The trial found that ivonescimab monotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared to pembrolizumab monotherapy.

The presentation will be held on Sunday, September 8, 2024, at 8:37 am PT / 11:37 am ET. The results will be presented in a late-breaking Presidential Symposium.

WEB HARMONi-2 is a randomized, double-blind, multiregional phase 3 trial of ivonescimab or placebo in patients with locally advanced or metastatic bladder cancer who have failed prior platinum-containing chemotherapy. The trial enrolled over 1,000 patients.

The findings from WEB HARMONi-2 are of major significance in the treatment of bladder cancer. They demonstrate the potential of ivonescimab as a new standard of care for patients with this aggressive disease.